Further, one recent clinical trial on SGLT-2 inhibitors suggests these beneficial effects may extend to patients with heart failure irrespective of diabetes, suggesting a mechanism independent of blood glucose-lowering [36]. Here, SLC5A2 is linked to heart failure.